gdc
PSSGuide_2021
Bladder Cancer

Drugs for Bladder Cancer (Urothelial Carcinoma)

Here are the drugs and financial support services available to patients receiving treatment for Bladder Cancer.

Balversa (erdafitinib)

Drug company: Janssen
833-375-3232

Balversa is a kinase inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) that has susceptible FGFR3 or FGFR2 genetic alteration (as determined by an FDA-approved test) and has progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Janssen offers 2 financial assistance programs for patients who have been prescribed Balversa:

Janssen CarePath Savings Program

With this program, eligible, privately insured patients will pay just $5 per month for Balversa, with an annual benefit up to $25,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.

Johnson & Johnson Patient Assistance Foundation

This program provides Balversa free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or enrolled in Medicare Part D.

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

Bavencio is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bavencio is also used as first-line maintenance treatment of patients with locally advanced or metastatic bladder cancer that has not progressed with firstline platinum-containing chemotherapy.

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

Through this program, patients with private insurance will be responsible for a $0 copay for Bavencio at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 annually.

CoverOne Patient Assistance Program

This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.

Imfinzi (durvalumab)

Drug company: AstraZeneca
844-275-2360

Imfinzi is a PD-L1 inhibitor used to treat patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neo-adjuvant or adjuvant treatment with platinum-containing chemotherapy.

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Imfinzi:

Imfinzi Co-pay Savings Program

Patients with private insurance will pay $0 per infusion of Imfinzi; this program pays the remaining out-of-pocket costs up to a maximum of $26,000 annually, with a program maximum of $100 per infusion assistance. Residents of Massachusetts, Michigan, Minnesota, and Rhode Island are not eligible for this assistance.

AZ&Me Prescription Savings Program

This prescription savings program offers free, mail-based medication to qualifying patients who have no insurance, those who have Medicare Part D coverage, and some patients with Medicare Part B coverage. General eligibility requirements include limited household income and/or a life-changing event in the past year that affected the patient’s finances. Patients with Medicare Part D coverage must spend 3% of their total household income on prescription medicines through a Medicare Part D prescription plan during the current calendar year, and must be unable to enroll in Medicare Limited Income Subsidy.

Patients with Medicare Part B coverage should call 800-292-6363 for program requirements. Once accepted into the program, patients will be enrolled for 1 year (with the option to re-enroll) and a supply of the medication (up to 90 days) will be sent directly to the patient. Refills need to be requested by the doctor or the patient.

Jelmyto (mitomycin)

Drug company: UroGen Pharma
855-535-6986

Jelmyto is a first-in-class alkylating drug, a pyelocalyceal solution used for the treatment of adults with low-grade upper tract urothelial cancer.

UroGen Support offers 2 financial assistance programs for patients who have been prescribed Jelmyto:

UroGen Support Copay Program

Eligible patients who have commercial or private health insurance will pay as little as $50 per dose of Jelmyto, with a maximum benefit of $4,000 per dose, and a maximum total benefit of up to $13,000 per year. To qualify for this program, patients must be enrolled in the UroGen Support Program.

UroGen Support Patient Assistance Program

Patients with no health insurance who are prescribed Jelmyto for an FDA-approved indication and have an adjusted gross income of up to 400% of the federal poverty level, may receive Jelmyto for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the first-line treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy and their tumor expresses PD-L1, as determined by an FDA-approved test; and as second-line treatment of patients whose disease has progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, regardless of PD-L1 status. Keytruda is also used for the treatment of patients with Bacillus Calmette-Guérin unresponsive, highrisk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $63,800 or less for individuals, $86,200 or less for a couple, or $131,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.

Bristol Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,280 for an individual or $51,720 for a family of 2.

Padcev (enfortumab vedotin-ejfv)

Drug company: Astellas Pharma
888-402-0627

Padcev is a Nectin-4-directed antibody and microtubule inhibitor conjugate used for the treatment of adults with locally advanced or metastatic bladder cancer (urothelial carcinoma) who have received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting.

Astellas Pharma Support Solutions offers 2 financial support programs for patients who have been prescribed Padcev:

Padcev Copay Assistance Program

Eligible patients who have private or commercial insurance will pay $5 per dose of Padcev, up to a maximum of $25,000 annual benefit. Patients will be enrolled in this program for 12 months. This program has no income requirements.

Padcev Patient Assistance Program

Eligible patients who have no insurance or have no insurance coverage for Padcev and meet the program requirements will receive Padcev free of charge.

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Tecentriq is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1, as determined by an FDA-approved test; and for patients who are not eligible for platinum-containing therapy, regardless of PD-L1 status.

Genentech Oncology offers 2 financial assistance programs for patients using Tecentriq:

Genentech Oncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.

Table. Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services
    Drug name (generic name)
  • Bavencio (avelumab)
  • Drug company
  • EMD Serono
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy

    First-line maintenance treatment of locally advanced or metastatic bladder cancer that has not progressed with firstline platinum-containing chemotherapy
  • Patient support services
  • CoverOne Co-Pay Assistance Program
    844-826-8371

    CoverOne Patient Assistance Program
    844-826-8371

    Drug name (generic name)
  • Imfinzi (durvalumab)
  • Drug company
  • AstraZeneca
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  • Patient support services
  • Imfinzi Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    844-275-2360


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • First-line treatment of locally advanced or metastatic bladder cancer for patients who are not eligible for cisplatin-containing therapy and whose tumors express PD-L1, as determined by an FDA-approved test

    Second-line treatment for patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status, whose disease progressed during or after platinum-based chemotherapy

    Treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

    Treatment of patients with Bacillus Calmette-Guérin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Opdivo (nivolumab)
  • Drug company
  • Bristol Myers Squibb
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer (urothelial carcinoma) that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003

    Drug name (generic name)
  • Padcev (enfortumab vedotin-ejfv)
  • Drug company
  • Astellas Pharma
  • Indication
  • Treatment of locally advanced or metastatic bladder (urothelial) cancer after treatment with a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting
  • Patient support services
  • Padcev Copay Assistance Program
    888-402-0627

    Padcev Patient Assistance Program
    888-402-0627

    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • Treatment of locally advanced or metastatic bladder cancer in patients who are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1, as determined by an FDA-approved test

    Treatment of patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status, or whose disease progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

Share this:

Last modified: April 8, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country